{"success":true,"data":{"pressRelease":{"id":"157242","rtpr_id":"nBw7xjtBsa-20260930","ticker":"INGN","exchange":"NASDAQ","all_tickers":["INGN"],"title":"Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech","author":"Business Wire","published_at":"2026-09-30T20:05:00.418Z","article_body":"Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech\n\nTransaction advances Inogen’s strategic shift toward a more streamlined\ncommercial model supporting higher revenue growth and adjusted operating\nincome\n\nInogen, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2F___http%3A%2Fwww.inogen.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo4OTYyMTBjM2Q2MzU2YjlhMjM5Mzc1M2RkYzRjYWJmNjo2OjY1ZmU6MDdlMWNlZWU1OGJiM2Y5NTc5NGFmNGNkNzNhZGViNzU5NTljMTIzYzk4MmZiOGE0NGQwMTU2NmI1Yzg3ODIwNDpwOlQ6Rg&esheet=54613618&newsitemid=20260930407827&lan=en-US&anchor=Inogen%2C+Inc.&index=1&md5=8f252f32223ca50d752a4d509c3e91b6)\n(Nasdaq: INGN\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2F___http%3A%2Fwww.inogen.com%2Finvestor___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo4OTYyMTBjM2Q2MzU2YjlhMjM5Mzc1M2RkYzRjYWJmNjo2OjYyYWE6YTFkYmIzOGM1MmRmOTk5YWI4M2NiY2ExOTE3YjEzMDM0NmU4YTc0NmE1MmJlNDlkN2NlZGU3ZjE3NDdiNDM0MDpwOlQ6Rg&esheet=54613618&newsitemid=20260930407827&lan=en-US&anchor=INGN&index=2&md5=0a6637ee4bcb257502d1e9acb9993c63)\n), a medical technology company offering innovative respiratory products for\nuse in the homecare setting, today announced that it has signed a definitive\nagreement to divest its U.S. oxygen rental business to Rotech Healthcare, a\nleading national provider of home respiratory and medical equipment. Under the\nagreement, Rotech will acquire specified rental assets for a total estimated\ncash consideration of up to $25 million. The transaction is expected to close\nin the fourth quarter of 2026, subject to customary closing conditions.\n\nSeparately, Inogen also signed a new, long-term supply agreement with Rotech,\nwhich is expected to support accelerating patient demand and access to\nInogen’s oxygen concentrators through Rotech’s national distribution\nnetwork.\n\nFollowing these transactions, Inogen will operate through a simpler, more\nfocused business model designed to drive greater patient access, faster growth\nand improved profitability. The Company will continue to leverage its core\ncompetencies in respiratory innovation, while partnering with leading home\nmedical equipment providers to expand the number of patients using Inogen\nproducts. Inogen remains committed to supporting patients, healthcare\nproviders and distributors, with patients continuing to have access to Inogen\nproducts through both distributors and its cash-pay direct-to-consumer sales\nchannel.\n\n“These transactions strengthen our business and financial profile, sharpen\nour strategic focus, and enable us to continue investing in innovative\nsolutions that improve patient outcomes,” said Kevin Smith, President and\nChief Executive Officer of Inogen. “Rotech’s strong reputation and\nrespiratory care expertise makes it a proven and trusted partner for our\npatients. Together, we are focused on providing a smooth transition for\npatients and ensuring continued access to high-quality oxygen therapy\nsolutions.”\n\nExpected Financial Impact\n\nInogen expects the transactions to increase both the revenue growth rate and\nadjusted operating income. The Rental Business generated revenue of $24.3\nmillion in the first half of 2026, representing a year-over-year decline of\n9.8%. Beginning with its financial results for the third quarter of 2026,\nInogen expects to present the Rental Business as discontinued operations,\nsubject to completion of the Company’s final accounting analysis. In\nconnection with its third-quarter earnings report, the Company expects to\nprovide additional information regarding the historical financial results of\nthe Rental Business and the impact of the transactions on Inogen’s outlook\nfor continuing operations.\n\nShare Repurchase Authorization Increase\n\nSubject to the closing of the transaction, Inogen’s Board of Directors has\napproved an increase of $15 million to the Company’s existing share\nrepurchase authorization, bringing the total authorization to $45 million and\nfurther enhancing Inogen’s ability to return capital to shareholders. The\nexpanded authorization will expire on June 30, 2028, or when the maximum\nauthorized dollar amount has been utilized, whichever occurs first. The\nCompany is under no obligation to purchase a specific number of shares, and\nthe program may be suspended or terminated at any time.\n\nAbout Inogen\n\nInogen, Inc. (Nasdaq: INGN) is a medical technology company offering\ninnovative respiratory products for use in the homecare setting. Inogen\nsupports patient respiratory care by developing, manufacturing, and marketing\ninnovative respiratory therapy devices used to deliver care to patients\nsuffering from chronic respiratory conditions. Inogen partners with patients,\nprescribers, home medical equipment providers and distributors to make its\nrespiratory therapy products widely available, allowing patients the chance to\nmanage the impact of their disease.\n\nFor more information, please visit www.inogen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.inogen.com&esheet=54613618&newsitemid=20260930407827&lan=en-US&anchor=www.inogen.com&index=3&md5=1881c201c4871546c0fbc135418fd657)\n.\n\nAbout Rotech Healthcare\n\nRotech Healthcare is a national leader in providing ventilators, oxygen, sleep\napnea treatment, wound care solutions, diabetes management, and home medical\nequipment. Rotech helps patients lead a more comfortable and productive life\nby keeping them engaged in their care and empowering them to manage their\nhealth and treatment at home.\n\nThe Rotech team is composed of talented, innovative, and experienced\nprofessionals – respiratory clinicians, customer service representatives,\nMedicare and insurance experts, patient service technicians, and many more.\nThey dedicate themselves to providing clinical excellence and exceptional,\nindustry-leading service to its patients and customers throughout the entire\npatient journey and consistently delivering on Rotech’s mission to “Get it\nRight the First Time.”\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nregarding the expected timing and completion of the transaction; the expected\nclassification of the Rental Business as discontinued operations; any\nanticipated net proceeds; the use of transaction proceeds; the Company’s\nshare repurchase program and anticipated share repurchases thereunder; the\nexpected impact on Inogen’s revenue growth, margins, profitability and\nfinancial profile; the transition and continued servicing of rental patients;\nmarket adoption of portable oxygen concentrators; Inogen’s go-to-market\nstrategy; future product launches and commercialization strategies; and\nInogen’s ability to drive growth, innovation and shareholder value.\nForward-looking statements are subject to risks and uncertainties that could\ncause actual results to differ materially from those anticipated, including\nrisks related to satisfaction of closing conditions, execution of the patient\ntransition, accounting treatment of the transaction, the amount of net\nproceeds ultimately received, the timing and amount of share repurchases,\nmarket acceptance of Inogen’s products, competition, reimbursement,\nInogen’s sales and distribution capabilities, planned product development\nand commercialization activities , Inogen’s ability to realize the benefits\nof the supply agreement and other risks associated with its operations.\nInformation on these and additional risks, uncertainties, and other\ninformation affecting Inogen’s business operating results are contained in\nits Annual Report on Form 10-K for the period ended December 31, 2025, its\nQuarterly Reports on Form 10-Q for the periods ended March 31, and June 30,\n2026, and in its other filings with the Securities and Exchange Commission.\nForward-looking statements speak only as of the date of this release, and\nInogen undertakes no obligation to update them except as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930407827/en/\n(https://www.businesswire.com/news/home/20260930407827/en/)\n\nir@inogen.net (mailto:ir@inogen.net)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7xjtBsa-20260930","title":"Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech","author":"Business Wire","ticker":"INGN","created":"2026-09-30T20:05:00.418Z","tickers":["INGN"],"exchange":"NASDAQ","article_body":"Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech\n\nTransaction advances Inogen’s strategic shift toward a more streamlined\ncommercial model supporting higher revenue growth and adjusted operating\nincome\n\nInogen, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2F___http%3A%2Fwww.inogen.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo4OTYyMTBjM2Q2MzU2YjlhMjM5Mzc1M2RkYzRjYWJmNjo2OjY1ZmU6MDdlMWNlZWU1OGJiM2Y5NTc5NGFmNGNkNzNhZGViNzU5NTljMTIzYzk4MmZiOGE0NGQwMTU2NmI1Yzg3ODIwNDpwOlQ6Rg&esheet=54613618&newsitemid=20260930407827&lan=en-US&anchor=Inogen%2C+Inc.&index=1&md5=8f252f32223ca50d752a4d509c3e91b6)\n(Nasdaq: INGN\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2F___http%3A%2Fwww.inogen.com%2Finvestor___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo4OTYyMTBjM2Q2MzU2YjlhMjM5Mzc1M2RkYzRjYWJmNjo2OjYyYWE6YTFkYmIzOGM1MmRmOTk5YWI4M2NiY2ExOTE3YjEzMDM0NmU4YTc0NmE1MmJlNDlkN2NlZGU3ZjE3NDdiNDM0MDpwOlQ6Rg&esheet=54613618&newsitemid=20260930407827&lan=en-US&anchor=INGN&index=2&md5=0a6637ee4bcb257502d1e9acb9993c63)\n), a medical technology company offering innovative respiratory products for\nuse in the homecare setting, today announced that it has signed a definitive\nagreement to divest its U.S. oxygen rental business to Rotech Healthcare, a\nleading national provider of home respiratory and medical equipment. Under the\nagreement, Rotech will acquire specified rental assets for a total estimated\ncash consideration of up to $25 million. The transaction is expected to close\nin the fourth quarter of 2026, subject to customary closing conditions.\n\nSeparately, Inogen also signed a new, long-term supply agreement with Rotech,\nwhich is expected to support accelerating patient demand and access to\nInogen’s oxygen concentrators through Rotech’s national distribution\nnetwork.\n\nFollowing these transactions, Inogen will operate through a simpler, more\nfocused business model designed to drive greater patient access, faster growth\nand improved profitability. The Company will continue to leverage its core\ncompetencies in respiratory innovation, while partnering with leading home\nmedical equipment providers to expand the number of patients using Inogen\nproducts. Inogen remains committed to supporting patients, healthcare\nproviders and distributors, with patients continuing to have access to Inogen\nproducts through both distributors and its cash-pay direct-to-consumer sales\nchannel.\n\n“These transactions strengthen our business and financial profile, sharpen\nour strategic focus, and enable us to continue investing in innovative\nsolutions that improve patient outcomes,” said Kevin Smith, President and\nChief Executive Officer of Inogen. “Rotech’s strong reputation and\nrespiratory care expertise makes it a proven and trusted partner for our\npatients. Together, we are focused on providing a smooth transition for\npatients and ensuring continued access to high-quality oxygen therapy\nsolutions.”\n\nExpected Financial Impact\n\nInogen expects the transactions to increase both the revenue growth rate and\nadjusted operating income. The Rental Business generated revenue of $24.3\nmillion in the first half of 2026, representing a year-over-year decline of\n9.8%. Beginning with its financial results for the third quarter of 2026,\nInogen expects to present the Rental Business as discontinued operations,\nsubject to completion of the Company’s final accounting analysis. In\nconnection with its third-quarter earnings report, the Company expects to\nprovide additional information regarding the historical financial results of\nthe Rental Business and the impact of the transactions on Inogen’s outlook\nfor continuing operations.\n\nShare Repurchase Authorization Increase\n\nSubject to the closing of the transaction, Inogen’s Board of Directors has\napproved an increase of $15 million to the Company’s existing share\nrepurchase authorization, bringing the total authorization to $45 million and\nfurther enhancing Inogen’s ability to return capital to shareholders. The\nexpanded authorization will expire on June 30, 2028, or when the maximum\nauthorized dollar amount has been utilized, whichever occurs first. The\nCompany is under no obligation to purchase a specific number of shares, and\nthe program may be suspended or terminated at any time.\n\nAbout Inogen\n\nInogen, Inc. (Nasdaq: INGN) is a medical technology company offering\ninnovative respiratory products for use in the homecare setting. Inogen\nsupports patient respiratory care by developing, manufacturing, and marketing\ninnovative respiratory therapy devices used to deliver care to patients\nsuffering from chronic respiratory conditions. Inogen partners with patients,\nprescribers, home medical equipment providers and distributors to make its\nrespiratory therapy products widely available, allowing patients the chance to\nmanage the impact of their disease.\n\nFor more information, please visit www.inogen.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.inogen.com&esheet=54613618&newsitemid=20260930407827&lan=en-US&anchor=www.inogen.com&index=3&md5=1881c201c4871546c0fbc135418fd657)\n.\n\nAbout Rotech Healthcare\n\nRotech Healthcare is a national leader in providing ventilators, oxygen, sleep\napnea treatment, wound care solutions, diabetes management, and home medical\nequipment. Rotech helps patients lead a more comfortable and productive life\nby keeping them engaged in their care and empowering them to manage their\nhealth and treatment at home.\n\nThe Rotech team is composed of talented, innovative, and experienced\nprofessionals – respiratory clinicians, customer service representatives,\nMedicare and insurance experts, patient service technicians, and many more.\nThey dedicate themselves to providing clinical excellence and exceptional,\nindustry-leading service to its patients and customers throughout the entire\npatient journey and consistently delivering on Rotech’s mission to “Get it\nRight the First Time.”\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nregarding the expected timing and completion of the transaction; the expected\nclassification of the Rental Business as discontinued operations; any\nanticipated net proceeds; the use of transaction proceeds; the Company’s\nshare repurchase program and anticipated share repurchases thereunder; the\nexpected impact on Inogen’s revenue growth, margins, profitability and\nfinancial profile; the transition and continued servicing of rental patients;\nmarket adoption of portable oxygen concentrators; Inogen’s go-to-market\nstrategy; future product launches and commercialization strategies; and\nInogen’s ability to drive growth, innovation and shareholder value.\nForward-looking statements are subject to risks and uncertainties that could\ncause actual results to differ materially from those anticipated, including\nrisks related to satisfaction of closing conditions, execution of the patient\ntransition, accounting treatment of the transaction, the amount of net\nproceeds ultimately received, the timing and amount of share repurchases,\nmarket acceptance of Inogen’s products, competition, reimbursement,\nInogen’s sales and distribution capabilities, planned product development\nand commercialization activities , Inogen’s ability to realize the benefits\nof the supply agreement and other risks associated with its operations.\nInformation on these and additional risks, uncertainties, and other\ninformation affecting Inogen’s business operating results are contained in\nits Annual Report on Form 10-K for the period ended December 31, 2025, its\nQuarterly Reports on Form 10-Q for the periods ended March 31, and June 30,\n2026, and in its other filings with the Securities and Exchange Commission.\nForward-looking statements speak only as of the date of this release, and\nInogen undertakes no obligation to update them except as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930407827/en/\n(https://www.businesswire.com/news/home/20260930407827/en/)\n\nir@inogen.net (mailto:ir@inogen.net)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-30T20:05:00.479727364Z","server_sent_at_ms":1790798700479},"received_at":"2026-09-30T20:05:00.533Z","source_url":"https://www.businesswire.com/news/home/20260930407827/en/"},"analysis":{"id":"145914","press_release_id":"157242","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["divested rental business revenue was declining 9.8% YoY","buyback increase contingent on transaction closing","closing subject to customary conditions; timing and net proceeds not guaranteed"],"eventType":"m_and_a","narrative":"Inogen signed a definitive agreement to divest its U.S. oxygen rental business to Rotech Healthcare for estimated cash consideration of up to $25 million, expected to close in Q4 2026.\n\nThe Rental Business generated $24.3 million of revenue in H1 2026, down 9.8% year-over-year; Inogen will present it as discontinued operations beginning with Q3 2026 results and expects the deal to raise revenue growth and adjusted operating income.\n\nInogen also signed a long-term supply agreement with Rotech, and its board approved a $15 million buyback authorization increase (to $45 million total), contingent on the transaction closing.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Inogen sheds its declining rental business and pivots to a leaner commercial model, backed by up to $25M in cash and an expanded $45M buyback."},"keyFigures":{"guidance":"Rental Business ($24.3M H1 2026 revenue, -9.8% YoY) to be presented as discontinued operations starting Q3 2026; transactions expected to increase revenue growth rate and adjusted operating income","dealValueUsd":25000000,"customDimensions":{"buyback_increase":15000000,"rental_business_revenue_yoy":"-9.8%","total_buyback_authorization":45000000,"rental_business_h1_2026_revenue":24300000}},"quotedText":"These transactions strengthen our business and financial profile, sharpen our strategic focus, and enable us to continue investing in innovative solutions that improve patient outcomes","namedEntities":{"people":[{"name":"Kevin Smith","role":"President and CEO of Inogen"}],"products":["Inogen oxygen concentrators"],"companies":[{"name":"Inogen, Inc.","ticker":"INGN","relationship":"filer/seller"},{"name":"Rotech Healthcare","relationship":"acquirer and supply-agreement partner"}],"dollarAmounts":[{"amount":"$25 million","context":"estimated total cash consideration for rental assets"},{"amount":"$24.3 million","context":"Rental Business revenue in H1 2026"},{"amount":"$15 million","context":"increase to share repurchase authorization"},{"amount":"$45 million","context":"total share repurchase authorization"}]},"materialImpact":{"score":4,"reasoning":"Divestiture of the U.S. oxygen rental business for up to $25 million reshapes Inogen's business model toward higher growth and adjusted operating income, paired with a $15 million buyback authorization increase and a long-term supply agreement with Rotech."},"tickerRelevance":{"others":[],"primary":"INGN"},"globalImportance":40,"audienceRelevance":35,"eventTypeSecondary":["buyback","partnership"],"importanceComponents":{"dealValue":"$25M","tickerTier":"small-cap","eventGravity":"divestiture restructuring business model","retailFavoriteBoost":false}},"event_type":"m_and_a","event_type_secondary":["buyback","partnership"],"sentiment":"bullish","material_impact_score":4,"narrative":"Inogen signed a definitive agreement to divest its U.S. oxygen rental business to Rotech Healthcare for estimated cash consideration of up to $25 million, expected to close in Q4 2026.\n\nThe Rental Business generated $24.3 million of revenue in H1 2026, down 9.8% year-over-year; Inogen will present it as discontinued operations beginning with Q3 2026 results and expects the deal to raise revenue growth and adjusted operating income.\n\nInogen also signed a long-term supply agreement with Rotech, and its board approved a $15 million buyback authorization increase (to $45 million total), contingent on the transaction closing.","key_figures":{"guidance":"Rental Business ($24.3M H1 2026 revenue, -9.8% YoY) to be presented as discontinued operations starting Q3 2026; transactions expected to increase revenue growth rate and adjusted operating income","dealValueUsd":25000000,"customDimensions":{"buyback_increase":15000000,"rental_business_revenue_yoy":"-9.8%","total_buyback_authorization":45000000,"rental_business_h1_2026_revenue":24300000}},"named_entities":{"people":[{"name":"Kevin Smith","role":"President and CEO of Inogen"}],"products":["Inogen oxygen concentrators"],"companies":[{"name":"Inogen, Inc.","ticker":"INGN","relationship":"filer/seller"},{"name":"Rotech Healthcare","relationship":"acquirer and supply-agreement partner"}],"dollarAmounts":[{"amount":"$25 million","context":"estimated total cash consideration for rental assets"},{"amount":"$24.3 million","context":"Rental Business revenue in H1 2026"},{"amount":"$15 million","context":"increase to share repurchase authorization"},{"amount":"$45 million","context":"total share repurchase authorization"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T20:05:06.331Z","global_importance":40,"audience_relevance":35,"importance_components":{"dealValue":"$25M","tickerTier":"small-cap","eventGravity":"divestiture restructuring business model","retailFavoriteBoost":false}},"durationMs":5753,"modelName":"glm-5.3-flashx"}}